Physician profile
Maddipoti Choudry
NPI 1053398495
$5,870.35
in general payments reported to CMS, 2019-2025
47 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,463 · 2020: $805 · 2021: $558 · 2022: $795 · 2023: $994 · 2024: $996 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,240 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,240.27 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $627.55 | 2019-2024 | |
| Glaxosmithkline, LLC. | $606.52 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $554.16 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $510.80 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $422.08 | 2019-2024 | Eliquis, Camzyos |
| Lilly USA, LLC | $348.98 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Regeneron Healthcare Solutions, INC. | $233.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $210.68 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.92 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.98 | 2021-2024 | Jardiance |
| Amgen INC. | $173.52 | 2019-2023 | Repatha, Otezla |
| Abbvie INC. | $125.85 | 2019-2021 | |
| Celgene Corporation | $115.18 | 2019 | |
| Merck Sharp & Dohme LLC | $112.15 | 2022-2024 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $110.16 | 2021-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maddipoti Choudry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.